IPP Bureau
Lupin partners global Agencies to support tuberculosis prevention treatment
By IPP Bureau - October 09, 2022
Through this agreement, Lupin will introduce two new formulations, a fixed-dose combination of Rifapentine + Isoniazid and Rifapentine 300 mg standalone tablets, at an affordable price
Nureca's subsidiary receives ISO 13485 certification for Indian medical device facility
By IPP Bureau - October 09, 2022
The certification will open new avenues for our flagship brand “Dr Trust”, enabling them to export these devices to many more countries
Thermo Fisher Scientific emphasizes on the need for more disruptive technologies
By IPP Bureau - October 09, 2022
Thermo Fisher is working closely with large pharmaceutical businesses to develop companion diagnostics in multiple areas such as heart disease, neurosciences and infectious diseases.
Dipharma receives regulatory authorization for the new line at Its cGMP pilot plant
By IPP Bureau - October 09, 2022
The company increases its efficiency and is able to face the growing demand for its services.
LISSUN announces 2nd edition of its campaign -'#LISSUNToYourMind'
By IPP Bureau - October 09, 2022
Campaign to celebrate World Mental Health Day theme "Mental Health in an Unequal World"
Pfizer acquires Global Blood Therapeutics
By IPP Bureau - October 09, 2022
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community
Pfizer announces positive topline results from Phase 3 TALAPRO-2 trial
By IPP Bureau - October 09, 2022
Study achieves primary endpoint of radiographic progression-free survival
BioMarin simplifies organizational structure to increase efficiency
By IPP Bureau - October 09, 2022
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
ICON selected by BARDA to conduct anthrax vaccine clinical trial
By IPP Bureau - October 09, 2022
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
Glenmark launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in adults
By IPP Bureau - October 07, 2022
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
Presss note on WHO Medical product alert regarding Maiden Pharmaceuticals
By IPP Bureau - October 07, 2022
DSCO has requested WHO to share at the earliest with CDSCO the report on establishment of causal relation to death with the medical products in question etc.
Zydus receives final approval from USFDA and 180 days shared exclusivity for Brivaracetam Tablets
By IPP Bureau - October 07, 2022
Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
L&T Construction bags order to construct manufacturing facility in Haryana
By IPP Bureau - October 07, 2022
This win is on the back of a prestigious order from Reliance Life Sciences
Lupin appoints Dr. Shahin Fesharaki as Global Chief Scientific Officer
By IPP Bureau - October 07, 2022
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
Atul Healthcare to acquire stake in VIMS
By IPP Bureau - October 05, 2022
The agreement provides for acquisition of 13,50,000 equity shares of Rs. 100 each constituting 50% of the total equity share capital
